IP Library Granted Patent US 8,183,044
Granted Patent B2
US 8,183,044 · App. 11/992,646 · Granted May 22, 2012

Recombinant human hepatitis C virus-like particle and method for producing the same

Assignees: Japan as represented by Director-General of National Institute of Infectious Diseases; Tokyo Metropolitan Institute of Medical Science; Toray Industries, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,183,044
App. No.
11/992,646
Granted
May 22, 2012
Kind
B2
Abstract

The present invention relates to a method for producing a recombinant hepatitis C virus-like particle comprising the steps of introducing into (i) a cell in which an RNA replicon comprising a nucleotide sequence comprising the 5′ untranslated region, the nucleotide sequence coding for the NS3, NS4A, NS4B, NS5A, and NS5B proteins, and the 3′ untranslated region of a genome RNA derived from a hepatitis C virus strain autonomously replicates, (ii) a vector expressing the Core, E1, E2, and p7 proteins derived from a hepatitis C virus strain that is the same as or different from that as defined in the above (i), culturing the cell, and recovering the produced virus-like particle, and a recombinant hepatitis C virus particle produced by this method.

Claims (13)

1. A method for producing a recombinant hepatitis C virus-like particle comprising, introducing into

(i) a cell carrying a subgenomic RNA replicon comprising a nucleotide sequence comprising the 5′ untranslated region, the nucleotide sequence coding for the NS3, NS4A, NS4B, NS5A, and NS5B proteins, and the 3′ untranslated region of a genome RNA derived from hepatitis C virus strain of genotype 1b which is a con1 strain or a strain derived therefrom,

(ii) a vaccinia virus vector or an EF-1α promoter carrying vector expressing the Core, E1, E2, and p7 proteins derived from at least one virus strain selected from the group consisting of hepatitis C virus strains of genotype 1a, 1b, 2a, 2b, 3a, and 3b that is different from the hepatitis C virus strain as defined in the (i),

culturing the cell, and recovering the produced virus-like particle.

2. The method according to claim 1 , wherein the hepatitis C virus strain of genotype 1a as defined in the (ii) is the H77c, 1, H, or HC-J1 strain.

3. The method according to claim 1 , wherein the hepatitis C virus strain of genotype 1b as defined in the (ii) is the J1, TH, J, JT, or BK strain.

4. The method according to claim 1 , wherein the hepatitis C virus strain of genotype 2a as defined in the (ii) is the JFH1, HC-J6, JCH1, or J6CF strain.

5. The method according to claim 1 , wherein the hepatitis C virus strain of genotype 3a as defined in the (ii) is the NZL1, K3a/650, 452, or E-b1 strain.

6. The method according to claim 1 , wherein the hepatitis C virus strain of genotype 3b as defined in the (ii) is the Tr strain.

7. The method according to claim 1 , wherein the RNA replicon further comprises at least one internal ribosome entry site (IRES) sequence and/or at least one foreign gene.

8. The method according to claim 1 , wherein the IRES sequence and/or the foreign gene is positioned between the 5′ untranslated region and the sequence coding for the NS3 protein.

9. The method according to claim 1 , wherein the cell is an animal cell.

10. The method according to claim 9 , wherein the animal cell is the Huh7 cell, the HepG2 cell, or an established cell line derived from these cells.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF 1ST ASSIGNEE PREVIOUSLY RECORDED ON REEL 020787 FRAME 0934. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT NAME IS AS FOLLOWS: JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES. Recorded Apr 3, 2012
From: TANABE, JUN-ICHI; SONE, SABURO; WAKITA, TAKAJI; ISHII, KOJI; SUZUKI, RYOSUKE; SUZUKI, TETSURO; MIYAMURA, TATSUO
To: JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES; TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE; TORAY INDUSTRIES, INC.
Reel/Frame 027983/0404 →
CHANGE OF NAME Recorded Sep 20, 2011
From: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH
To: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
Reel/Frame 026931/0980 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2008
From: TANABE, JUN-ICHI; SONE, SABURO; WAKITA, TAKAJI; ISHII, KOJI; SUZUKI, RYOSUKE; SUZUKI, TETSURO; MIYAMURA, TATSUO
To: JAPAN AS REPRESENTED BY DIRECTOR GENERAL OFAGENCY OF SHINSHU UNIVERSITY; TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH; TORAY INDUSTRIES, INC.
Reel/Frame 020787/0934 →
Priority Claims (1)
JP 2005-287825 · Sep 30, 2005 · national
Continuity (1)
Related Publication 20090221028A1 · Sep 3, 2009